Monday, March 27, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biosecurity

IVI Initiates MERS Vaccine Research and Development

by Global Biodefense Staff
September 7, 2015
MERS CoV Coronavirus

The International Vaccine Institute (IVI) in South Korea has announced it will launch a project to accelerate the research and development of vaccines for Middle East Respiratory Syndrome, a viral respiratory illness caused by the Middle East Respiratory Syndrome Coronavirus (MERS-CoV).

First detected in 2012 in Saudi Arabia, MERS-CoV has been reported in several countries, causing 1,478 cases and 516 deaths globally. It was responsible for a recent outbreak in South Korea with 185 cases and 36 deaths reported. There is currently no vaccine or antiretroviral treatment for MERS-CoV infection.

Samsung Medical Center will support the effort with a grant of $34 million over five years. The funding will be used to identify the most promising vaccines currently ready for testing and to begin human studies as quickly and safely as possible.

IVI is in the process of discussion and partnering with groups that have data suggesting protection in animal models and anticipates = an initial set of collaborators to be assembled shortly.

“We are extremely grateful to Samsung for their very generous contribution,” said Dr. Jerome Kim, IVI’s Director General, “Thanks to Samsung, we will be able to harness the best resources and capabilities in Korea and internationally to develop new, safe and effective MERS vaccines.”

On September 10, the Institute will host the 2015 Shinil-IVI Global Vaccine Forum: International MERS Symposium in Seoul, South Korea. Sponsored by Shinil and the Korea Support Committee for the IVI (KSC), the symposium will convene leading scientists and experts in public health, infectious diseases and vaccine development from Korea and internationally. They will present the latest translational and clinical research on MERS-CoV, and discuss opportunities for the development of MERS-CoV countermeasures, particularly in the area of vaccines.

Tags: Animal ModelsAwardsCoronavirusMERS-CoV

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
Load More

Latest News

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC